The FDA granted 510(k) clearance to market a molecular assay for the detection of group B streptococcus (GBS) and for its revogene molecular diagnostics instrument by GenePOC.
The GenePOC GBS LB assay and revogene instrument is a cost-effective diagnostics solution for the point-of-care market.